Safe and affordable antivenoms on the horizon
Venomous snakebites affect 2.5 million and kill around 100 000 people each year. Conventional antivenoms often cause severe side effects and anaphylaxis in patients and are costly to manufacture. The EU-funded MABSTER project will develop a cost-effective approach to identify and engineer human monoclonal antibodies with special toxin-binding properties making them sensitive to regulation by the microenvironment (e.g. pH). Project research will harness phage display selection, high-density peptide microarray technology, and antibody engineering methods to discover and develop human monoclonal antibodies that are broadly cross-reactive, enabling them to neutralise several different venom toxins at the same time. Successful outcome of the project might generate new ways to design biotherapeutics for other complex indications, such as cancer as well as infectious and parasitic diseases.
Fields of science
Call for proposal
See other projects for this call